PBS updates

Vimpat (Lacosamide)

lacosamide 10 mg/mL oral liquid, 200 mL · ORAL · PBS code 11694L

STREAMLINED

What it costs

AU$51.71 PBS-determined price per 6 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2019-05-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Intractable focal onset seizures


Initial treatment


Must be treated by a neurologist; AND

The treatment must be in combination with two or more antiseizure medications which include one second-line adjunctive agent; AND

The condition must have failed to be controlled satisfactorily by other antiseizure medications, which include at least one first-line antiseizure agent and at least two second-line adjunctive antiseizure agents.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Intractable focal onset seizures


Continuing treatment


Patient must have previously received PBS-subsidised treatment with this drug for this condition.

Sponsor: UCB Australia Proprietary Limited ABN 48 005 799 208

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.